PCSK9: A new participant in lipophagy in regulating atherosclerosis?
Saved in:
| Title: | PCSK9: A new participant in lipophagy in regulating atherosclerosis? |
|---|---|
| Authors: | Xiao, Jun1 (AUTHOR), Deng, Yi-Min1 (AUTHOR), Liu, Xiang-Rui1 (AUTHOR), Cao, Jian-Ping1 (AUTHOR), Zhou, Min1 (AUTHOR), Tang, Ya-Ling1 (AUTHOR), Xiong, Wen-Hao1 (AUTHOR), Jiang, Zhi-Sheng1 (AUTHOR), Tang, Zhi-Han1 (AUTHOR) Tangzhihan98@163.com, Liu, Lu-Shan1 (AUTHOR) liuls2000@163.com |
| Source: | Clinica Chimica Acta. Aug2019, Vol. 495, p358-364. 7p. |
| Subjects: | Lipid metabolism, Lysosomes, Low density lipoprotein receptors, Lipoprotein receptors, Atherosclerosis |
| Abstract: | Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis. • Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation; • Lipophagy plays an important role in the prevention of atherosclerosis by removing excessive lipids; • PCSK9 participates in lipid metabolism through the lipophagy pathway, and thus affects atherosclerosis. [ABSTRACT FROM AUTHOR] |
| Copyright of Clinica Chimica Acta is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 137072866 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: PCSK9: A new participant in lipophagy in regulating atherosclerosis? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Xiao%2C+Jun%22">Xiao, Jun</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Deng%2C+Yi-Min%22">Deng, Yi-Min</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Xiang-Rui%22">Liu, Xiang-Rui</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+Jian-Ping%22">Cao, Jian-Ping</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhou%2C+Min%22">Zhou, Min</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tang%2C+Ya-Ling%22">Tang, Ya-Ling</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xiong%2C+Wen-Hao%22">Xiong, Wen-Hao</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jiang%2C+Zhi-Sheng%22">Jiang, Zhi-Sheng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tang%2C+Zhi-Han%22">Tang, Zhi-Han</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> Tangzhihan98@163.com</i><br /><searchLink fieldCode="AR" term="%22Liu%2C+Lu-Shan%22">Liu, Lu-Shan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> liuls2000@163.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Clinica+Chimica+Acta%22">Clinica Chimica Acta</searchLink>. Aug2019, Vol. 495, p358-364. 7p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Lipid+metabolism%22">Lipid metabolism</searchLink><br /><searchLink fieldCode="DE" term="%22Lysosomes%22">Lysosomes</searchLink><br /><searchLink fieldCode="DE" term="%22Low+density+lipoprotein+receptors%22">Low density lipoprotein receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Lipoprotein+receptors%22">Lipoprotein receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Atherosclerosis%22">Atherosclerosis</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis. • Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation; • Lipophagy plays an important role in the prevention of atherosclerosis by removing excessive lipids; • PCSK9 participates in lipid metabolism through the lipophagy pathway, and thus affects atherosclerosis. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Clinica Chimica Acta is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=137072866 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.cca.2019.05.005 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 7 StartPage: 358 Subjects: – SubjectFull: Lipid metabolism Type: general – SubjectFull: Lysosomes Type: general – SubjectFull: Low density lipoprotein receptors Type: general – SubjectFull: Lipoprotein receptors Type: general – SubjectFull: Atherosclerosis Type: general Titles: – TitleFull: PCSK9: A new participant in lipophagy in regulating atherosclerosis? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Xiao, Jun – PersonEntity: Name: NameFull: Deng, Yi-Min – PersonEntity: Name: NameFull: Liu, Xiang-Rui – PersonEntity: Name: NameFull: Cao, Jian-Ping – PersonEntity: Name: NameFull: Zhou, Min – PersonEntity: Name: NameFull: Tang, Ya-Ling – PersonEntity: Name: NameFull: Xiong, Wen-Hao – PersonEntity: Name: NameFull: Jiang, Zhi-Sheng – PersonEntity: Name: NameFull: Tang, Zhi-Han – PersonEntity: Name: NameFull: Liu, Lu-Shan IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2019 Type: published Y: 2019 Identifiers: – Type: issn-print Value: 00098981 Numbering: – Type: volume Value: 495 Titles: – TitleFull: Clinica Chimica Acta Type: main |
| ResultId | 1 |